{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T20:11:43Z","timestamp":1790626303034,"version":"4.1.0"},"reference-count":54,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T00:00:00Z","timestamp":1409097600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir. j. psychol. Med."],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:p>Pregabalin is a<jats:italic>\u03b3<\/jats:italic>-aminobutyric acid analogue that is primarily prescribed in psychiatry for management of generalized anxiety disorder. The belief in its low potential for abuse has placed it in a superior position to other anxiolytic agents. However, more recent, concerns have been raised about the addictive potential of pregabalin. This problem has not received much attention nor has the mechanism of its development. There is also a lack of understanding of the difference in the experience of abusing pregabalin in contrast to abusing other illicit drugs. We report the case of a 55-year-old patient with a background history of multiple psychoactive substances misuse who elaborated on his own personal experience of pregabalin abuse. He consumed a month\u2019s supply of this medication over 2 days and realized an enhancement in sexual desire and excitement. This effect should be considered when prescribing pregabalin.<\/jats:p>","DOI":"10.1017\/ipm.2014.41","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T10:07:16Z","timestamp":1409134036000},"page":"281-286","source":"Crossref","is-referenced-by-count":12,"title":["Pregabalin abuse for enhancing sexual performance: case discussion and literature review"],"prefix":"10.1017","volume":"31","author":[{"given":"M.","family":"Osman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,8,27]]},"reference":[{"key":"S079096671400041X_ref39","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-6109.2011.02518.x"},{"key":"S079096671400041X_ref38","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.3.533"},{"key":"S079096671400041X_ref37","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e3282fb7629"},{"key":"S079096671400041X_ref36","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e31817275a5"},{"key":"S079096671400041X_ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04104.x"},{"key":"S079096671400041X_ref6","doi-asserted-by":"publisher","DOI":"10.1097\/01.ftd.0000158874.54100.1a"},{"key":"S079096671400041X_ref35","doi-asserted-by":"publisher","DOI":"10.1002\/hup.937"},{"key":"S079096671400041X_ref32","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0511"},{"key":"S079096671400041X_ref128","first-page":"43633","article-title":"Schedules of Controlled Substances: Placement of Pregabalin Into Schedule V","volume":"70","author":"Leonhart","year":"2005","journal-title":"Federal Register"},{"key":"S079096671400041X_ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02381.x"},{"key":"S079096671400041X_ref25","unstructured":"ICD 10 Online (2010). WHO: Geneva. (http:\/\/apps.who.433 int\/classifications\/icd10\/browse\/2010\/en#\/F40-F48) Accessed on 28 November 2012."},{"key":"S079096671400041X_ref40","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000155820.74832.b0"},{"key":"S079096671400041X_ref15","first-page":"152","article-title":"Gabapentin and pregabalin: abuse and addiction","volume":"21","year":"2012","journal-title":"Prescrire International"},{"key":"S079096671400041X_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0922-4106(93)90156-4"},{"key":"S079096671400041X_ref21","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2010.09091269"},{"key":"S079096671400041X_ref41","first-page":"616","article-title":"A case series of recreational pregabalin overdose resulting in generalized seizures","volume":"48","author":"Reedy","year":"2010","journal-title":"Clinical Toxicology"},{"key":"S079096671400041X_ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9137-5"},{"key":"S079096671400041X_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000084032.22282.ff"},{"key":"S079096671400041X_ref11","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2008.0035"},{"key":"S079096671400041X_ref7","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-0656"},{"key":"S079096671400041X_ref4","unstructured":"BCAP (2012). Prescribing and Therapeutics Shared Care Guidelines for Pregabalin for Refractory Neuropathic Pain (http:\/\/www.bathdiabetes.org\/resources\/268.pdf). Accessed 11 December 2012."},{"key":"S079096671400041X_ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2006.04.005"},{"key":"S079096671400041X_ref2","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e328333d574"},{"key":"S079096671400041X_ref27","first-page":"CD003592","article-title":"Antidepressants for generalized anxiety disorder","volume":"2003","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S079096671400041X_ref1","doi-asserted-by":"crossref","first-page":"2101.e1","DOI":"10.1016\/j.ajem.2012.02.008","article-title":"Complete atrioventricular block due to overdose of pregabalin","volume":"30","author":"Aksaka","year":"2012","journal-title":"American Journal of Emergency Medicine"},{"key":"S079096671400041X_ref49","doi-asserted-by":"publisher","DOI":"10.3109\/9780203092835"},{"key":"S079096671400041X_ref33","unstructured":"National Institute for Health and Clinical Excellence (2007). Anxiety (amended). Management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. Clinical Guidance 22, April (http:\/\/www.nice.org.uk)."},{"key":"S079096671400041X_ref44","doi-asserted-by":"publisher","DOI":"10.1159\/000321079"},{"key":"S079096671400041X_ref3","doi-asserted-by":"publisher","DOI":"10.2147\/nedt.2007.3.2.185"},{"key":"S079096671400041X_ref22","unstructured":"Health and Social Board Headquarters in Belfast (2012). Office of Assistant Director of Integrated Care\u2013Pharmacy & Medicines Management: Misuse and Diversion Potential of Pregabalin (Lyrica), 6 November (http:\/\/www.hscboard.hscni.net\/medicinesmanagement\/Correspondence\/082%20November%202012%20-%20Letter%20-%20Pregabalin%20Misuse%20-%20PDF%2060KB.pdf).Accessed 12 December 2012."},{"key":"S079096671400041X_ref48","doi-asserted-by":"publisher","DOI":"10.1080\/15563650801986497"},{"key":"S079096671400041X_ref31","first-page":"162","article-title":"A case of pregabalin intoxication","volume":"23","author":"Miljevic","year":"2012","journal-title":"Psychiatriki"},{"key":"S079096671400041X_ref12","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2012.720971"},{"key":"S079096671400041X_ref29","first-page":"772","article-title":"A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care","volume":"53","author":"Lenox-Smith","year":"2003","journal-title":"The British Journal of General Practice"},{"key":"S079096671400041X_ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2005.12.001"},{"key":"#cr-split#-S079096671400041X_ref9.1","unstructured":"5. Canadian Agency for Drugs and Technologies in Health (CADTH) (2012). Rapid response report, summary with critical appraisal, abuse and misuse potential for pregabalin"},{"key":"#cr-split#-S079096671400041X_ref9.2","unstructured":"6. a review of the clinical evidence, 24 April 2012 (http:\/\/dpic.org\/sites\/default\/files\/PregabalinAbuse_CADTH_24Apr2012.pdf). Accessed 11 December 2012."},{"key":"S079096671400041X_ref47","first-page":"44","article-title":"Pregabalin \u2013 a drug with abuse potential?","volume":"229","author":"Skopp","year":"2012","journal-title":"Archiv f\u00fcr Kriminologie"},{"key":"S079096671400041X_ref53","first-page":"CD009429","article-title":"Pregabalin monotherapy for epilepsy","volume":"17","author":"Zhou","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"S079096671400041X_ref14","unstructured":"European Medicines Agency (2006). Lyrica \u2013 scientific discussion, European Medicines Agency, London."},{"key":"S079096671400041X_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.0013-9580.2004.455003.x"},{"key":"S079096671400041X_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2011.05.054"},{"key":"S079096671400041X_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4603(02)00266-6"},{"key":"S079096671400041X_ref8","doi-asserted-by":"publisher","DOI":"10.2174\/1876523801104010008"},{"key":"S079096671400041X_ref50","doi-asserted-by":"publisher","DOI":"10.5350\/KPB-BCP201121110"},{"key":"S079096671400041X_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(91)90150-A"},{"key":"S079096671400041X_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2006.02.004"},{"key":"S079096671400041X_ref18","first-page":"605","article-title":"Potential for pregabalin abuse or diversion after past drug-seeking behaviour","volume":"110","author":"Filipetto","year":"2010","journal-title":"The Journal of the American Osteopathic Association"},{"key":"S079096671400041X_ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2011.10.023"},{"key":"S079096671400041X_ref42","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.749"},{"key":"S079096671400041X_ref43","first-page":"1902","volume-title":"Kaplan and Sadock\u2019s Comprehensive Textbook of Psychiatry","author":"Saddock","year":"2005"},{"key":"S079096671400041X_ref46","first-page":"828","article-title":"Pregabalin (Pfizer)","volume":"2","author":"Selak","year":"2001","journal-title":"Current Opinion in Investigational Drugs"},{"key":"S079096671400041X_ref51","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02966.x"},{"key":"S079096671400041X_ref45","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0853-y"}],"container-title":["Irish Journal of Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S079096671400041X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T07:31:56Z","timestamp":1689492716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S079096671400041X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,27]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S079096671400041X"],"URL":"https:\/\/doi.org\/10.1017\/ipm.2014.41","relation":{},"ISSN":["0790-9667","2051-6967"],"issn-type":[{"value":"0790-9667","type":"print"},{"value":"2051-6967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,27]]}}}